Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

NCT03485209 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT03485209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03485209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 25, 2018
Completion date
March 31, 2027
Enrollment
350 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, squamous cell of head and neck, colorectal neoplasms, exocrine pancreatic cancer